CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Operating activities
Net (loss) income	$ (1,884)	$ (3,701)	$ (2,141)	$ 5,432	$ (7,161)	$ 1,435
Adjustments to reconcile net income (loss) to net cash provided (used) by operating activities:
Depreciation of property and equipment					1,369	1,333
Amortization of intangible assets					1,290	1,298
Non-cash lease expense					885	1,123
Provision for bad debt, net					435	(30)
Stock-based compensation					322	391
Gain on disposal of discontinued operations					0	(5,159)
Amortization of loan issuance costs					104	141
Write-off of borrowing costs					0	130	$ (4,200)	$ (2,500)
Gain on disposal of MD Office Solutions					0	(847)
(Gain) loss on sale of assets					156	29
Gain on Paycheck Protection Program loan forgiveness					0	(4,179)
Deferred income taxes					226	34
Unrealized loss (gain) of equity securities and lumber derivatives					2,132	381
Changes in operating assets and liabilities:
Accounts receivable					1,622	(3,131)
Inventories					(4,539)	(193)
Other assets					(848)	(1,032)
Accounts payable					1,817	(709)
Accrued compensation					345	582
Deferred revenue and billings in excess of costs and estimated profit					1,035	1,383
Operating lease liabilities					(865)	(1,100)
Other liabilities					1,441	(56)
Net cash provided (used) by operating activities					(234)	(8,176)
Investing activities
Purchases of property and equipment					(1,232)	(675)
Proceeds from sale of discontinued operations					0	18,750
Proceeds from sale of property and equipment					217	76
Purchases of equity securities					(3,994)	(399)
Proceeds from sales of equity securities					27	42
Net cash provided (used) by investing activities					(4,982)	17,794
Financing activities
Proceeds from borrowings					80,061	91,309
Repayment of debt					(81,152)	(97,594)
Proceeds from the sale of common stock, warrants, and exercise of over allotment options					13,198	0
Fees paid on issuance of common stock					(450)	0
Proceeds from exercise of warrants					0	567
Fees paid on issuance of rights agreement					0	(28)
Taxes paid related to net share settlement of equity awards					(5)	(18)
Repayment of obligations under finance leases					(466)	(595)
Preferred stock dividends paid					(1,437)	(958)
Net cash provided (used) by financing activities					9,749	(7,317)
Net increase in cash, cash equivalents, and restricted cash including cash classified within current assets held for sale					4,533	2,301
Less: net increase in cash classified within current assets held for sale					0	(46)
Net increase in cash, cash equivalents, and restricted cash					4,533	2,347
Cash, cash equivalents, and restricted cash at beginning of period		$ 4,816		$ 3,393	4,816	3,393	3,393
Cash, cash equivalents, and restricted cash at end of period	9,349		5,740		9,349	5,740	4,816	3,393
Reconciliation of cash, cash equivalents, and restricted cash at end of year
Cash and cash equivalents	8,503		5,572		8,503	5,572	4,538
Restricted cash	846		168		846	168	278
Cash, cash equivalents, and restricted cash at end of period	$ 9,349		$ 5,740		9,349	5,740	$ 4,816	$ 3,393
Non-Cash Investing Activities
MD Office Solutions Promissory Note Receivable					0	1,385
Non-Cash Financing Activities
Gain on Paycheck Protection Program Loan Forgiveness					0	4,179
Noncash property, plant, and equipment obtained in exchange for finance lease liabilities					90	0
Noncash right-of-use assets obtained in exchange for operating lease liabilities					$ 1,436	$ 1,532